Immuron Ltd — Capital/Financing Update 2007

Aug 30, 2007

==> picture [67 x 76] intentionally omitted <==

Company Announcement

Anadis Completes Capital Raising securing $700,000 from local and US investors

Friday 31 August 2007

Melbourne, Australia - Anadis Ltd. (ASX:ANX), a leading biotechnology company focused on polyclonal antibodies to address human disease is pleased to announce that it has commitments for over $700,000 from investors in Australia and the US to further support its research and commercialisation efforts.

The placement was issued at a price of 14c per share (representing a 6.33% discount to the 5 day VWAP ending 17[th] August 2007), plus one 18c option for every three shares, with a 12 month expiry. The raise enhances our cash position in addition to the recently announced $5 million equity credit line facility the company had signed with Fortrend (see “Anadis Secures Standby Subscription Agreement” 18 June 2007)

Zeil Rosenberg, Anadis CEO stated: “The proceeds of the capital, will assist in strengthening the cash position of the Company as it moves forward with our innovative business strategy, to focus on expanding our R&D program and leveraging our intellectual property and know-how to become the leading developer and provider of polyclonal antibodies worldwide”.

Members of the Anadis Board and their related parties have participated in the capital raising with significant new cash investment. Issuance of shares subscribed to by directors (and related parties) of the company (1,214,285 shares and 404,761 options relating to $168,000 of new investment) will be issued following and subject to shareholder approval at the Company’s Annual General Meeting in November.

Exact number of new shares issued is yet to be announced due to exchange rate variations.

Shareholder Share Purchase Plan

Anadis is please to offer qualifying shareholders the opportunity to participate in a Share Purchase Plan “SPP” at the same issue price of shares offered in the placement.

This SPP gives all qualifying Anadis shareholders the opportunity to invest in the shares of the Company at $0.14c a share up to a maximum of $5,000 per beneficiary. The record date for the SPP has been set at 5:00pm (AEST) on Friday, 31 August 2007 and offer documents for participation in the SPP are expected to be forwarded to eligible shareholders on or about 18 September 2007.

==> picture [48 x 55] intentionally omitted <==

For further information contact:

Dr Zeil Rosenberg (US) - CEO Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Arie Nudel – Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

Richard Allen – Media Email: richard@oxygenpr.com.au Tel: +61 3 9915 6341

==> picture [48 x 55] intentionally omitted <==